NASDAQ$RAPT

RAPT Therapeutics Inc · Q3 2018 earnings

Q3 2018 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.59

No prior period
Net Income

-$10.3M

No prior period
Operating Income

-$10.5M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$9.18M

No prior period

Revenue & EPS history

RAPT · Revenue · Quarterly

$0

Q3 2025
Beat estimate in 4 of 5 quarters(80%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 8 quarterly earnings reports

Historical avg

-1.6%

Avg return

Earnings day

-11.5%

Avg return

5 days after

-5.0%

Avg return

30 days after

44%

11 / 25 earnings

Positive

+38.7%

Q3 2022

Best reaction

-45.8%

Q3 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025+2.6%+4.5%+21.9%
Q2 2025+1.0%+8.6%+28.1%
Q1 2025+0.0%-8.3%+46.2%
Q4 2024-0.9%+0.9%-6.2%
Q3 2024-10.3%-37.1%-41.7%
Q2 2024-5.8%+2.5%-23.3%
Q1 2024-45.7%-50.1%-51.8%
Q4 2023-0.7%-13.0%-13.6%
Q3 2023+8.2%
Q2 2023-4.8%
Q1 2023-3.5%
Q4 2022-28.4%
Q3 2022+38.7%
Q2 2022+18.7%
Q1 2022+9.7%
Q4 2021+9.2%
Q3 2021-1.9%
Q2 2021-0.4%
Q1 2021-4.0%
Q4 2020+12.0%
Q3 2020-45.8%
Q2 2020+12.3%
Q1 2020+3.7%
Q4 2019+8.7%
Q3 2019-12.3%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro